Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sparano

Showing results (511-520 of 560) with videos related to

Pageof 56
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2015
Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105Melinda L Telli, Kristin C Jensen, Shaveta Vinayak, et al.
JAMA Oncology|January 18, 2019
Association of Magnetic Resonance Imaging and a 12-Gene Expression Assay With Breast Ductal Carcinoma In Situ TreatmentConstance D Lehman, Constantine Gatsonis, Justin Romanoff, et al.
NPJ Breast Cancer|July 20, 2017
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trialKerin Adelson, Bhuvaneswari Ramaswamy, Joseph A Sparano, et al.
Radiology|April 1, 2025
MRI-based Radiomic Features for Risk Stratification of Ductal Carcinoma in Situ in a Multicenter Setting (ECOG-ACRIN E4112 Trial)Kalina P Slavkova, Ruya Kang, Anum S Kazerouni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2024
A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11Vered Stearns, Opeyemi A Jegede, Victor T-S Chang, et al.
JAMA Oncology|April 12, 2019
Current Landscape of Immunotherapy in Breast Cancer: A ReviewSylvia Adams, Margaret E Gatti-Mays, Kevin Kalinsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 6, 2021
E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research GroupRoisin M Connolly, Fengmin Zhao, Kathy D Miller, et al.
NPJ Breast Cancer|October 12, 2019
Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancerDavid B Page, Harry Bear, Sangeetha Prabhakaran, et al.
Clinical Breast Cancer|June 5, 2019
Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 StudyDenise A Yardley, Lowell Hart, Anne Favret, et al.
NPJ Breast Cancer|January 6, 2026
Racial disparity in pro-metastatic tumor microenvironment in treatment naïve breast cancerPriyanka Parmar, Burcu Karadal-Ferrena, Suryansh Shukla, et al.
Pageof 56

Showing results (511-520 of 560) with videos related to

Sort By:
Pageof 56
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2015
Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105Melinda L Telli, Kristin C Jensen, Shaveta Vinayak, et al.
JAMA Oncology|January 18, 2019
Association of Magnetic Resonance Imaging and a 12-Gene Expression Assay With Breast Ductal Carcinoma In Situ TreatmentConstance D Lehman, Constantine Gatsonis, Justin Romanoff, et al.
NPJ Breast Cancer|July 20, 2017
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trialKerin Adelson, Bhuvaneswari Ramaswamy, Joseph A Sparano, et al.
Radiology|April 1, 2025
MRI-based Radiomic Features for Risk Stratification of Ductal Carcinoma in Situ in a Multicenter Setting (ECOG-ACRIN E4112 Trial)Kalina P Slavkova, Ruya Kang, Anum S Kazerouni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2024
A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11Vered Stearns, Opeyemi A Jegede, Victor T-S Chang, et al.
JAMA Oncology|April 12, 2019
Current Landscape of Immunotherapy in Breast Cancer: A ReviewSylvia Adams, Margaret E Gatti-Mays, Kevin Kalinsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 6, 2021
E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research GroupRoisin M Connolly, Fengmin Zhao, Kathy D Miller, et al.
NPJ Breast Cancer|October 12, 2019
Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancerDavid B Page, Harry Bear, Sangeetha Prabhakaran, et al.
Clinical Breast Cancer|June 5, 2019
Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 StudyDenise A Yardley, Lowell Hart, Anne Favret, et al.
NPJ Breast Cancer|January 6, 2026
Racial disparity in pro-metastatic tumor microenvironment in treatment naïve breast cancerPriyanka Parmar, Burcu Karadal-Ferrena, Suryansh Shukla, et al.
Pageof 56